Fasting plasma glucose beats HbA1c for diabetes screening

Fasting plasma glucose beats HbA1c for diabetes screening
For patients without diabetes undergoing coronary angiography, fasting plasma glucose performs better in diabetes screening than glycated hemoglobin, according to a study published online Dec. 13 in Diabetes Care.

(HealthDay)—For patients without diabetes undergoing coronary angiography (CAG), fasting plasma glucose (FPG) performs better in diabetes screening than glycated hemoglobin (HbA1c), according to a study published online Dec. 13 in Diabetes Care.

Jun-Sing Wang, M.D., from the Taichung Veterans General Hospital in Taiwan, and colleagues compared HbA1c and FPG as screening tools for diabetes using an (OGTT) in 400 patients without known diabetes undergoing CAG. OGTT and HbA1c were assessed two to four weeks after hospital discharge.

The researchers note that 20.8 percent of the patients were diagnosed with diabetes. FPG had a higher area under the receiver operating characteristic curve than HbA1c (0.81 versus 0.73; P = 0.032). A proposed screening algorithm was validated in an additional group of 170 patients. The algorithm had a sensitivity of 74.4 percent and a specificity of 100 percent and reduced the number of OGTTs by 71.4 percent.

"In summary, we reported that the FPG test performed better than HbA1c in screening for diabetes in patients undergoing CAG," the authors write. "We proposed a screening algorithm, and its efficacy and practicability need further investigation."

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Meds adherence self-report valid in type 2 diabetes

date Dec 20, 2012

(HealthDay)—Self-reported measures of medication adherence in adults with type 2 diabetes are valid, although some self-reports are moderated by depression, according to a study published online Nov. 30 ...

Recommended for you

Adapted diabetes prevention program deemed effective

date 9 hours ago

(HealthDay)—An adapted Diabetes Prevention Program (DPP) lifestyle intervention significantly improves cardiovascular disease-related risk factors among participants, according to a study published in the ...

Diabetes drug helps people lose weight: study

date Jul 01, 2015

Liraglutide, an injectable diabetes drug that US regulators approved last year for weight loss, helped obese people lose an average of 18 pounds (eight kilograms), a yearlong study said Wednesday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.